Aline Dechanet
YOU?
Author Swipe
View article: sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial Open
We investigated whether baseline levels of biomarkers related to endotheliopathy, thromboinflammation, and fibrosis were associated with clinical outcomes in hospitalized COVID-19 patients. We analyzed the associations between baseline lev…
View article: Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20–15 DisCoVeRy study
Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20–15 DisCoVeRy study Open
View article: Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19
Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19 Open
View article: An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 Open
View article: Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial Open
Background Lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a and hydroxychloroquine efficacy for COVID-19 have been evaluated, but detailed evaluation is lacking. Objective To determine the efficacy of lopinavir/ritonavir, lop…
View article: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial—authors’ response
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial—authors’ response Open
comorbidities, possible myocarditis and kidney injuries and drugdrug interactions. 9Models suggested that doses .600mg twice daily may prolong QTc intervals with consequences warranting safety considerations. 7With a 400 mg loading dose fo…